* The LibreView website is only compatible with certain operating systems and browsers. Please check www.libreview.com for additional information.
Better outcomes. Clinically proven in patients with T1D and T2D.1-3
Both real-world evidence and clinical trial results show improved outcomes with the FreeStyle Libre 2 system.1-3
Proven outcomes
Associated with a 43% increase in time in target range
(3.9-10.0 mmol/L) from 11.7 to 16.8 hours a day with increased scan rate
(p<0.001)5
Associated with a 63% reduction in time spent above 13.3 mmol/L
across patients with diabetes5 (p<0.001)
Associated with a 43% reduction in time spent <3.9 mmol/L
in patients with T2D (p<0.001)6
0.4% reduction in A1C8
Increased time in target range by 1 hour/day8
(3.9-10.0 mmol/L)
Reduced time spent in hyperglycemia (>10 mmol/L) by 1 hour/day
with no significant increase in time spent in hypoglycemia (<3.9 mmol/L).8
Increased the frequency of glucose monitoring to an average of 8x per day
vs. CBG.8
Increased monitoring means improved self-management9
Clinically proven accuracy10
Excellent accuracy at a glance
9.2%
Overall MARD10
The lower the MARD, the more accurate the results
99.9%
in zones A+B
of consensus error grid10
Measurement errors associated with these zones have no effect on clinical action, and little or no effect on clinical outcomes.10
Trusted accuracy, even when glucose is low, falling or rapidly changing.10
-
Outstanding accuracy in the low glucose range (<3.9 mmol/L)10 -
98.8% of results for levels <3.9 mmol/L are within ±1.1 mmol/L of blood glucose measurements11
Clinically proven to be accurate10 over 14 days in pediatric patients
9.7%
Overall MARD
The lower the MARD, the more accurate the results10
100%
in zones A+B
of consensus error grid10
Measurement errors associated with these zones have no effect on clinical action, and little or no effect on clinical outcomes.10
Outstanding low-end accuracy where it matters most10
-
Low glucose range (<3.9 mmol/L)
-
98.8% of results in this range are within ±1.1 mmol/L of blood glucose measures11
Parents and caregivers can rely on the FreeStyle Libre 2 system to make treatment decisions even when glucose is low, falling or rapidly changing.
CBG=capillary blood glucose; MARD=mean absolute relative difference; YSI=Yellow Springs Instrument.
The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle Libre 2 app requires registration with LibreView.
References:
- Evans M, Welsh Z, Seibold A. Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies. Diabetes Ther. 2022;13(6):1175-1185. doi:10.1007/s13300-022-01253-9.
- Bolinder J, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388(10057):2254-2263. doi:10.1016/S0140-6736(16)31535-5.
- Roussel R, et al. Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Diabetes Care. 2021;44(6):1368-1376. doi:10.2337/dc20-1690.
- Wright EE Jr, et al. Use of flash glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr 2021;34(2):184-89.
- Lang J, et al. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control [Abstract 089]. Diabetes Technol Ther 2019;21(1):A40.
- Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73.
- Fokkert M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care 2019;7(1):e000809.
- Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 2018;19(7):1294-301.
- Aronson R, et al. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes Obes Metab. 2023;25(4):1024‐1031. doi:10.1111/dom.14949.
- Alva S, et al. Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes. J Diabetes Sci Technol. 2022;16(1):70-77. doi:10.1177/1932296820958754.
- Data on file, Abbott Diabetes Care, Inc.
STAY CONNECTED